On January 23, 2026, Mirum Pharmaceuticals, Inc. finalized the acquisition of Bluejay Therapeutics, Inc., acquiring approximately $56.6 million in cash and committing up to $280.8 million in cash and 4,673,597 shares of stock as part of the merger agreement.